Lexicon Pharma shares halted pending news

Mar. 22, 2019 12:52 PM ETLexicon Pharmaceuticals, Inc. (LXRX), SNYSNY, LXRXBy: Douglas W. House, SA News Editor11 Comments
  • Nasdaq has suspended trading in Lexicon Pharmaceuticals (LXRX -5.3%) pending the release of news, a near-certainty that it pertains to the expected FDA nod for Sanofi's (SNY -2.6%) oral Zynquista (sotagliflozin) for type 1 diabetes. Today is the agency's action date.
  • Sanofi in-licensed the dual SGLT-1 & 2 inhibitor from Lexicon in November 2015.
  • Approval should trigger a milestone payment to LXRX.

Recommended For You

Comments (11)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.